Journal articles: 'Disease-Specific Symptoms'

1

Dissanayaka, Nadeeka N. W., John D. O'Sullivan, Nancy A. Pachana, Rodney Marsh, Peter A. Silburn, Elizabeth X. White, Elizabeth Torbey, George D. Mellick, David A. Copland, and Gerard J. Byrne. "Disease-specific anxiety symptomatology in Parkinson's disease." International Psychogeriatrics 28, no. 7 (February 10, 2016): 1153–63. http://dx.doi.org/10.1017/s1041610215002410.

Full text

Abstract:

ABSTRACTBackground:Symptoms of anxiety relating to Parkinson's disease (PD) occur commonly and include symptomatology associated with motor disability and complications arising from PD medication. However, there have been relatively few attempts to profile such disease-specific anxiety symptoms in PD. Consequently, anxiety in PD is underdiagnosed and undertreated. The present study characterizes PD-related anxiety symptoms to assist with the more accurate assessment and treatment of anxiety in PD.Methods:Ninety non-demented PD patients underwent a semi-structured diagnostic assessment targeting anxiety symptoms using relevant sections of the Mini International Neuropsychiatric Interview (MINI-plus). In addition, they were assessed for the presence of 30 PD-related anxiety symptoms derived from the literature, the clinical experience of an expert panel and the PD Anxiety-Motor Complications Questionnaire (PDAMCQ). The onset of anxiety in relation to the diagnosis of PD was determined.Results:Frequent (>25%) PD-specific anxiety symptoms included distress, worry, fear, agitation, embarrassment, and social withdrawal due to motor symptoms and PD medication complications, and were experienced more commonly in patients meeting DSM-IV criteria for an anxiety disorder. The onset of common anxiety disorders was observed equally before and after a diagnosis of PD. Patients in a residual group of Anxiety Not Otherwise Specified had an onset of anxiety after a diagnosis of PD.Conclusion:Careful characterization of PD-specific anxiety symptomatology provides a basis for conceptualizing anxiety and assists with the development of a new PD-specific measure to accurately assess anxiety in PD.

APA, Harvard, Vancouver, ISO, and other styles

2

Pavlik, E., C. DeSimone, R. Miller, I. Podzielinski, J. Ubellacker, S. Goodrich, F. Ueland, L. Seamon, R. Kryscio, and J. van Nagell. "Women without ovarian cancer reporting disease-specific symptoms." Gynecologic Oncology 120 (March 2011): S80—S81. http://dx.doi.org/10.1016/j.ygyno.2010.12.192.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Krause, Ivonne, Simone Kern, Antje Horntrich, and Tjalf Ziemssen. "Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors." Multiple Sclerosis Journal 19, no. 13 (May 1, 2013): 1792–99. http://dx.doi.org/10.1177/1352458513485655.

Full text

Abstract:

Background: Multiple sclerosis (MS) is associated with high rates of early retirement (ER). Objectives: A German cohort of MS patients and healthy control subjects (HCs) were compared cross-sectionally to investigate disease- and non-disease-specific factors that are associated with employment status (ES) in MS and to identify predictors of ES in MS. Methods: A total of 39 ER MS patients, 48 employed MS patients, and 37 HCs completed a brief neuropsychological battery and questionnaires related to depressive symptoms, fatigue, health-related quality of life (HrQoL) and health locus of control (HLC). Neurological disability was assessed by the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC). Results: ER compared with employed MS patients scored significantly higher in neurological disability, depressive symptoms and fatigue and significantly lower in cognitive functioning and HrQoL. Further, both groups differed with regard to age, education, disease course and duration but not in HLC. Neurological disability, age and fatigue were identified as significant predictors of ES in MS. Conclusions: ES in MS was associated with demographic aspects, neurological and cognitive status, depressive symptoms, fatigue and HrQoL but was not associated with HLC. Findings confirm neurological disability, age and fatigue as independent predictors of ES in MS.

APA, Harvard, Vancouver, ISO, and other styles

4

Steiger, Malcolm, Sui Wong, Joanne Crossley, Nick Fletcher, Gus Baker, and Udo Wieshmann. "ARE THERE NON–MOTOR SYMPTOMS SPECIFIC TO PARKINSON'S DISEASE?" Journal of Neurology, Neurosurgery & Psychiatry 84, no. 11 (October 9, 2013): e2.75-e2. http://dx.doi.org/10.1136/jnnp-2013-306573.166.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Portillo, Carmen J., William L. Holzemer, and Fang-Yu Chou. "HIV Symptoms." Annual Review of Nursing Research 25, no. 1 (January 2007): 259–91. http://dx.doi.org/10.1891/0739-6686.25.1.259.

Full text

Abstract:

People with HIV/AIDS are a vulnerable group whose symptoms can seriously affect their quality of life. HIV/AIDS symptoms can result from the disease itself, from secondary complications of the disease, or from side-effects of highly active antiretroviral therapy (HAART) and other medications related to comorbidities. HIV symptoms are the single most important indicators for patients and practitioners. Symptoms prompt patients to seek medical attention and provide health care providers with essential clues about changes in health status and quality of life. Despite increased recognition of the importance of addressing symptoms among people with HIV/AIDS, few studies have examined the management of HIV symptoms. This chapter introduces HIV symptoms, reports on the methods of review, provides an overview of contextual issues including the literature on symptoms, issues related to symptom measures, theoretical foundations on symptom management, HIV-specific measures, non-HIV-specific measures, translation of findings into practice, and implications for future research and policy.

APA, Harvard, Vancouver, ISO, and other styles

6

Van der Velden, SK, NH Shadid, PJ Nelemans, and A. Sommer. "How specific are venous symptoms for diagnosis of chronic venous disease?" Phlebology: The Journal of Venous Disease 29, no. 9 (January 3, 2014): 580–86. http://dx.doi.org/10.1177/0268355513515859.

Full text

Abstract:

Objective The objective of this study is to evaluate whether and which ‘venous’ symptoms are characteristic for patients affected with chronic venous disease compared to patients with other diseases of the lower limbs (e.g. arthrosis, peripheral arterial disease, spinal disc herniation). Methods A cross-sectional study was performed to compare the frequency of venous symptoms among 76 patients with chronic venous disease and reflux and 74 patients with other diseases of the legs without reflux. The VEINES-Sym of the VEINES-QOL/Sym questionnaire was used to evaluate the frequency of symptoms. Demographic, clinical classification and ultrasound findings were also noted. Results A total of 122 patients were included for analysis (response rate of 87%). Presence of venous symptoms was slightly more often reported in the chronic venous disease group than in the non-chronic venous disease group, but differences were small and statistically non-significant. Severity of chronic venous disease as classified by the CEAP classification was not associated with higher proportions of patients reporting symptoms than in non-chronic venous disease patients, except for swelling ( p = .016) and itching ( p = .007) in C3-C6 patients. The largest difference between the chronic venous disease and non-chronic venous disease group was observed for the time of the day at which symptoms were most intense; patients with chronic venous disease were more likely to experience symptoms at the end of the day ( p < .001). Conclusions The small differences in prevalence of reported ‘venous’ symptoms between chronic venous disease patients and patients with other diseases of the legs suggest that these symptoms may be less specific for patients with chronic venous disease and refluxing veins than is usually assumed.

APA, Harvard, Vancouver, ISO, and other styles

7

Luo, Fangfang, and Xu Luo. "Intelligent Disease Prediagnosis Only Based on Symptoms." Journal of Healthcare Engineering 2021 (July 31, 2021): 1–9. http://dx.doi.org/10.1155/2021/9963576.

Full text

Abstract:

People often concern the relationships between symptoms and diseases when seeking medical advices. In this paper, medical data are divided into three copies, records related to main disease categories, records related to subclass disease types, and records of specific diseases firstly; then two disease recognition methods only based on symptoms for the main disease category identification, subclass disease type identification, and specific disease identification are given. In the methods, a neural network and a support vector machine (SVM) algorithms are adopted, respectively. In the method validation part, accuracy of the two diagnosis methods is tested and compared. Results show that automatic disease prediction only based on symptoms is possible for intelligent medical triage and common disease diagnosis.

APA, Harvard, Vancouver, ISO, and other styles

8

Vermeiren, Yannick, Debby Van Dam, Tony Aerts, Sebastiaan Engelborghs, and Peter P. De Deyn. "Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease." Journal of Alzheimer's Disease 41, no. 3 (July 16, 2014): 819–33. http://dx.doi.org/10.3233/jad-140309.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kimball, A., M. Sundaram, A. Mathias, C. Foley, and A. Shields. "Measuring Disease specific impact and symptoms among patients with Hidradenitis Suppurativa." Value in Health 18, no. 3 (May 2015): A183—A184. http://dx.doi.org/10.1016/j.jval.2015.03.1061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Prabhu, R., G. Rodrigues, Y. S. Sarma, and R. Benakatti. "Non-pancreatic retroperitoneal pseudocyst: a benign disease with non-specific symptoms." Case Reports 2013, jul02 1 (July 2, 2013): bcr2013200184. http://dx.doi.org/10.1136/bcr-2013-200184.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Cook, Joan M., Jane L. Pearson, and Anthony H. Ahrens. "General and specific events and depressive symptoms in Alzheimer's disease caregivers." American Journal of Alzheimer's Disease 12, no. 1 (January 1997): 32–34. http://dx.doi.org/10.1177/153331759701200107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Bressler, Brian, Kevin P. Bethel, Ralf Kleef, Sophie L. Reynolds, Simon Sutcliffe, David W. Mullins, and Hal Gunn. "Site-Specific Immunomodulator: A Novel Treatment for Crohn’s Disease." Gastroenterology Research and Practice 2015 (2015): 1–7. http://dx.doi.org/10.1155/2015/231243.

Full text

Abstract:

We investigated the mechanism of action, safety, and efficacy of the Site-Specific Immunomodulator (SSI) QBECO, a novel immunotherapy for Crohn’s disease (CD). Using human monocytic THP-1 cells, we demonstrate that SSI QBECO (derived from the common colon bacteriaE. coli) activates macrophages to an M1 phenotype (associated with enhanced capacity to eliminate bacteria and activate innate immune responses). We assessed SSI QBECO in a compassionate use protocol of ten adult patients with active CD. Patients with moderate to severe clinical symptoms receiving conventional CD treatments and/or complementary therapies were included, except patients receiving anti-TNF medications. SSI QBECO was self-administered subcutaneously every second day, for a minimum of 2.5 months and a maximum of 11 months. All 10 patients reported improvement of symptoms while on the SSI QBECO treatment. Seven patients reported full resolution of clinical symptoms during a course of SSI QBECO of at least three months. Three patients have experienced ongoing sustained clinical remission after discontinuing all medications, including SSI treatment. The longest case of clinical remission is still ongoing (>4 years). No serious severe adverse clinical events were reported. Collectively, we conclude that treatment with the immunoactive SSI QBECO was well tolerated and effective for treatment of Crohn’s disease in this case series.

APA, Harvard, Vancouver, ISO, and other styles

13

Reisberg, Barry. "Behavioral Intervention Approaches to the Treatment and Management of Alzheimer's Disease: A Research Agenda." International Psychogeriatrics 8, S1 (October 1996): 39–44. http://dx.doi.org/10.1017/s1041610296003067.

Full text

Abstract:

Alzheimer's disease (AD) is a progressive condition associated with a broad variety of clinical symptoms. These symptoms can, for the most part, be conceptualized as falling within three primary categories: (I) cognitive symptoms, (II) functional symptoms, and (III) behavioral (disturbance) symptoms. All of these symptom categories may potentially respond to specific behavioral intervention approaches to treatment and management. However, at this time, few behavioral approaches have convincingly been substantiated to be effective in treating any of the symptoms in any of these categories.

APA, Harvard, Vancouver, ISO, and other styles

14

Seresirikachorn, K., J. Mullol, K. Limitlaohaphan, V. Asvapoositkul, and K. Snidvongs. "Leukotriene receptor antagonist addition to intranasal steroid: systematic review and meta-analysis." Rhinology journal 59, no. 1 (February 1, 2021): 2–9. http://dx.doi.org/10.4193/rhin20.126.

Full text

Abstract:

Background: Intranasal corticosteroids (INCS) and leukotriene receptor antagonist (LTRA) have different mechanisms of action. The combination of INCS and LTRA (INCS+LTRA) are utilized to control the allergic rhinitis (AR) symptoms. The effects of this com- bination have not been made evident yet. Methodology: Randomized controlled trials studying the effects of INCS+LTRA vs INCS in monotherapy on rhinoconjunctivitis symptoms in patients with AR were included. Data were pooled for meta-analysis. The outcomes were nasal symptoms, ocular symptoms, disease-specific quality of life (QOL), and adverse events. Results: Six studies (358 participants) met the inclusion criteria. There were no differences between INCS+LTRA and INCS mono- therapy on composite nasal symptom score, total daytime symptom score, total night time symptom score, disease-specific QOL and adverse events. The results favoured the effects of INCS-LTRA on ocular symptoms. Conclusions: The effects of the INCS+LTRA combination are not different from INCS in monotherapy in the improvement of both nasal symptoms and patient's QOL. The combination may, however, be better on improving ocular symptoms.

APA, Harvard, Vancouver, ISO, and other styles

15

Morton, Hannah, Kevin C. Pedley, Robin J. C. Stewart, and Jane Coad. "Inflammatory Bowel Disease: Are Symptoms and Diet Linked?" Nutrients 12, no. 10 (September 29, 2020): 2975. http://dx.doi.org/10.3390/nu12102975.

Full text

Abstract:

New Zealand (NZ) has one of the world’s highest incidence rates of Inflammatory Bowel Disease (IBD), a group of chronic inflammatory conditions that affect the gastrointestinal tract. Patients with IBD often believe certain foods influence their disease symptoms and consequently may alter their diet considerably. The objective of this study was to determine foods, additives, and cooking methods (dietary elements) that NZ IBD patients identify in the onset, exacerbation, or reduction of their symptoms. A total of 233 participants completed a self-administered questionnaire concerning symptom behaviour in association with 142 dietary elements. Symptom onset and symptom exacerbation were associated with dietary elements by 55% (128) and 70% (164) of all IBD participants, respectively. Fruit and vegetables were most frequently identified, with dairy products, gluten-containing bread, and foods with a high fat content also considered deleterious. Of all IBD participants, 35% (82) associated symptom reduction with dietary elements. The identified foods were typically low in fibre, saturated fatty acids, and easily digestible. No statistically significant differences were seen between the type or number of dietary elements and disease subtype or recent disease activity. The association between diet and symptoms in patients with IBD and the mechanism(s) involved warrant further research and may lead to the development of IBD specific dietary guidelines.

APA, Harvard, Vancouver, ISO, and other styles

16

Li, Xiao-Ling, Nan Hu, Meng-Shan Tan, Jin-Tai Yu, and Lan Tan. "Behavioral and Psychological Symptoms in Alzheimer’s Disease." BioMed Research International 2014 (2014): 1–9. http://dx.doi.org/10.1155/2014/927804.

Full text

Abstract:

Neuropsychiatric symptoms (NPS) such as depression, apathy, aggression, and psychosis are now recognized as core features of Alzheimer’s disease (AD), and there is a general consensus that greater symptom severity is predictive of faster cognitive decline, loss of independence, and even shorter survival. Whether these symptoms result from the same pathogenic processes responsible for cognitive decline or have unique etiologies independent of AD-associated neurodegeneration is unclear. Many structural and metabolic features of the AD brain are associated with individual neuropsychiatric symptoms or symptom clusters. In addition, many genes have been identified and confirmed that are associated with symptom risk in a few cases. However, there are no single genes strongly predictive of individual neuropsychiatric syndromes, while functional and structural brain changes unique to specific symptoms may reflect variability in progression of the same pathological processes. Unfortunately, treatment success for these psychiatric symptoms may be lower when comorbid with AD, underscoring the importance of future research on their pathobiology and treatment. This review summarizes some of the most salient aspects of NPS pathogenesis.

APA, Harvard, Vancouver, ISO, and other styles

17

Tetreault, Aaron M., Tony Phan, Dana Orlando, Ilwoo Lyu, Hakmook Kang, Bennett Landman, and R. Ryan Darby. "Network localization of clinical, cognitive, and neuropsychiatric symptoms in Alzheimer’s disease." Brain 143, no. 4 (March 16, 2020): 1249–60. http://dx.doi.org/10.1093/brain/awaa058.

Full text

Abstract:

Abstract There is both clinical and neuroanatomical variability at the single-subject level in Alzheimer’s disease, complicating our understanding of brain-behaviour relationships and making it challenging to develop neuroimaging biomarkers to track disease severity, progression, and response to treatment. Prior work has shown that both group-level atrophy in clinical dementia syndromes and complex neurological symptoms in patients with focal brain lesions localize to brain networks. Here, we use a new technique termed ‘atrophy network mapping’ to test the hypothesis that single-subject atrophy maps in patients with a clinical diagnosis of Alzheimer’s disease will also localize to syndrome-specific and symptom-specific brain networks. First, we defined single-subject atrophy maps by comparing cortical thickness in each Alzheimer’s disease patient versus a group of age-matched, cognitively normal subjects across two independent datasets (total Alzheimer’s disease patients = 330). No more than 42% of Alzheimer’s disease patients had atrophy at any given location across these datasets. Next, we determined the network of brain regions functionally connected to each Alzheimer’s disease patient’s location of atrophy using seed-based functional connectivity in a large (n = 1000) normative connectome. Despite the heterogeneity of atrophied regions at the single-subject level, we found that 100% of patients with a clinical diagnosis of Alzheimer’s disease had atrophy functionally connected to the same brain regions in the mesial temporal lobe, precuneus cortex, and angular gyrus. Results were specific versus control subjects and replicated across two independent datasets. Finally, we used atrophy network mapping to define symptom-specific networks for impaired memory and delusions, finding that our results matched symptom networks derived from patients with focal brain lesions. Our study supports atrophy network mapping as a method to localize clinical, cognitive, and neuropsychiatric symptoms to brain networks, providing insight into brain-behaviour relationships in patients with dementia.

APA, Harvard, Vancouver, ISO, and other styles

18

Rosenbloom, S. K., J. Beaumont, P. Diaz, S. E. Yount, A. P. Abernethy, P. B. Jacobsen, D. Paul, K. Syrjala, J. H. Von Roenn, and D. Cella. "Patient-centered validation of 11 symptom indices to evaluate response to chemotherapy for advanced cancer." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 6524. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.6524.

Full text

Abstract:

6524 Background: Symptom burden in advanced disease has relevance both for clinical practice and in evaluating the efficacy of new chemotherapeutic agents. This study aimed to identify patients’ highest priority symptoms for 11 advanced cancers, compare priority ratings with those obtained from clinicians, and construct brief symptom indices based on their combined input. Methods: 534 patients with advanced bladder, brain, breast, colorectal, head/neck, hepatobiliary/pancreatic, kidney, lung, lymphoma, ovarian or prostate cancer from a subset of National Comprehensive Cancer Network (NCCN) member institutions and 4 Cancer Health Alliance of Metropolitan Chicago organizations completed a survey of priority symptoms and concerns and a disease-specific FACT QOL measure. 112 physicians at NCCN institutions completed a rating of whether symptoms and concerns were considered disease- or treatment-related. Symptoms endorsed more often than chance probability were retained. Expert clinician and patient ratings were equally weighted in item selection. Responses to symptom index items drawn from the QOL questionnaires allowed for validation analyses. Results: Items comprising 2 to 3 subscales (up to 20 items in length) were retained for each of the 11 disease-specific symptom indices. Content-determined subscales consisted of symptoms and concerns that were 1) exclusively or predominantly disease-related symptoms (DRS); 2) exclusively or predominantly treatment side effects (TSE); and 3) descriptive of general function or well-being (F/WB). For example, the NCCN/FACT Breast Cancer Symptom Index (FBSI) contains 17 items: 8 DRS, 4 TSE and 5 F/WB. Data on 14 of 17 FBSI items showed good internal consistency (a=.89). Correlations between FBSI and FACT-B scores were high for physical well-being, functional well-being and breast cancer subscales (r = 0.83, 0.77, and 0.61 respectively). Correlation with emotional well-being subscale was 0.55. FBSI scores differed across PSR groups in the appropriate direction (p<0.0001). Conclusions: NCCN/FACT disease-specific questionnaires have been transformed into brief, patient-centered symptom indices that can be used as stand-alone measures in oncology research and practice. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

19

Azmin, Shahrul, Abdul Manaf Khairul Anuar, Hui Jan Tan, Wan Yahya Nafisah, Azman Ali Raymond, Othman Hanita, Shamsul Azhar Shah, and Mohamed Ibrahim Norlinah. "Nonmotor Symptoms in a Malaysian Parkinson’s Disease Population." Parkinson's Disease 2014 (2014): 1–7. http://dx.doi.org/10.1155/2014/472157.

Full text

Abstract:

Background. The nonmotor symptoms are important determinants of health and quality of life in Parkinson’s disease but are not well recognized and addressed in clinical practice. This study was conducted to determine the prevalence of nonmotor symptoms and their impact on quality of life in patients with Parkinson’s disease.Methods. This was a cross-sectional study among patients with idiopathic Parkinson’s disease. Exclusion criteria were a Mini Mental State Examination score of <21/30. Prevalence of nonmotor symptoms was determined using the NMSQuest. The severity of nonmotor symptoms and the quality of life were assessed using validated disease-specific questionnaires (PDQ-39 and NMSS).Results. A total of 113 patients consisting of 60 males and 53 females were recruited. The median duration of illness was 5.0 (2.0–8.0) years. The prevalence rate of nonmotor symptoms in our cohort was 97.3%. The most common reported nonmotor symptom in our cohort was gastrointestinal (76.1%). We found that the severity of the nonmotor symptoms was associated with poorer quality of life scores (rs: 0.727,P<0.001).Conclusions. Nonmotor symptoms were highly prevalent in our patients with Parkinson’s disease and adversely affected the quality of life of our patients. In contrast to western studies, the most common nonmotor symptom is gastrointestinal. The possibility of an Asian diet playing a role in this observation requires further study.

APA, Harvard, Vancouver, ISO, and other styles

20

Whisenant, Meagan S., Faith A. Strunk, Debasish Tripathy, and Loretta A. Williams. "HSR19-112: Qualitative Development of a Patient-Reported Outcome Measure of Symptom Burden in Breast Cancer." Journal of the National Comprehensive Cancer Network 17, no. 3.5 (March 8, 2019): HSR19–112. http://dx.doi.org/10.6004/jnccn.2018.7146.

Full text

Abstract:

Background: The use of disease-specific patient-reported outcomes (PROs) is critical for facilitating individualized symptom monitoring and improving cancer patient outcomes. The MD Anderson Symptom Inventory (MDASI) is a PRO measure of symptom burden. The purpose of this study was to describe the patient experience and define the content domain for the MDASI module specific to breast cancer (MDASI-Br). Methods: 36 patients with breast cancer across the disease and treatment continuum described their experience in single qualitative interviews. Content analysis was used to define the symptom burden content domain. An expert panel scored the relevance on a 0–4 scale (4 = relevant) of the symptoms identified from the qualitative interviews. Symptoms were selected for inclusion in the MDASI-Br if they met at least 1 of the following criteria: (1) mean relevance rating of ≥3 by the expert panel, (2) described by ≥20% of patients in qualitative interviews, or (3) core MDASI items. Results: Participants had a mean age of 57.9 years, 86.1% had stage I–III, and 52.8% were on active treatment. 36 symptoms were identified, with 14 reported by ≥20% of participants. Symptoms varied among participants based on disease stage and treatment modality. Fatigue and distress were described by most women regardless of treatment, whereas arm swelling was reported only by women who had undergone surgery, and skin changes were reported primarily by women who received radiation therapy. Patients volunteered ways in which symptoms affected daily functioning. 21 symptoms were included in the MDASI-Br for psychometric testing, including 6 breast cancer-specific symptoms: breast changes, hot flashes, constipation, arm swelling, fingernail or toenail changes, and skin changes. Two additional symptoms, vaginal dryness and decrease in sexual interest or activity, were included because they are common to endocrine therapy. Conclusions: Patients with breast cancer experience numerous but distinct symptoms related to disease and treatment that may result in interference with daily activities, relationships, life plans, treatment adherence, and mood. Various treatments result in unique symptom burden. The content domain for a PRO symptom-burden measure of breast cancer encompasses the diversity, severity, and activity interference of common symptoms of breast cancer and its treatment.

APA, Harvard, Vancouver, ISO, and other styles

21

Szymkowicz, Sarah M., Vonetta M. Dotson, Jacob D. Jones, Michael S. Okun, and Dawn Bowers. "Symptom Dimensions of Depression and Apathy and Their Relationship With Cognition in Parkinson’s Disease." Journal of the International Neuropsychological Society 24, no. 3 (October 16, 2017): 269–82. http://dx.doi.org/10.1017/s1355617717001011.

Full text

Abstract:

AbstractObjectives: Both depression and apathy, alone and in combination, have been shown to negatively affect cognition in patients with Parkinson’s disease (PD). However, the influence of specific symptom dimensions of depression and apathy on cognition is not well understood. The current study investigated the relationship between symptom dimensions of depression and apathy, based on factors identified in Kirsch-Darrow et al. (2011), and memory and executive function in PD. Methods: A sample of 138 non-demented individuals with PD (mean age=64.51±7.43 years) underwent neuropsychological testing and completed the Beck Depression Inventory, 2nd Edition, and Apathy Scale. Separate hierarchical regression models examined the relationship between symptom dimensions of depression and apathy (“pure” depressive symptoms, “pure” apathy, loss of interest/pleasure [anhedonia], and somatic symptoms) and three cognitive domain composites: immediate verbal memory, delayed verbal memory, and executive function. Results: After adjusting for general cognitive status and the influence of the other symptom dimensions, “pure” depressive symptoms were negatively associated with the delayed verbal memory composite (p<.034) and somatic symptoms were positively associated with the executive function composite (p<.026). No symptom dimensions were significantly related to the immediate verbal memory composite. Conclusions: Findings suggest that specific mood symptoms are associated with delayed verbal memory and executive function performance in non-demented patients with PD. Further research is needed to better understand possible mechanisms through which specific symptom dimensions of depression and apathy are associated with cognition in PD. (JINS, 2018, 24, 269–282)

APA, Harvard, Vancouver, ISO, and other styles

22

Palanica, Adam, Anirudh Thommandram, Yan Fossat, and Carmen Rodriguez-Blazquez. "Eliciting clinical empathy via transmission of patient-specific symptoms of Parkinson’s disease." Cogent Psychology 5, no. 1 (January 1, 2018): 1526459. http://dx.doi.org/10.1080/23311908.2018.1526459.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Smeets, F. G. M., A. A. M. Masclee, J. M. Conchillo, and D. Keszthelyi. "Systematic review: Disease-specific instruments to assess gastrointestinal symptoms in functional dyspepsia." Neurogastroenterology & Motility 30, no. 8 (March 9, 2018): e13327. http://dx.doi.org/10.1111/nmo.13327.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Doering, Lynn V., Sharon McKinley, Barbara Riegel, Debra K. Moser, Hendrika Meischke, Michele M. Pelter, and Kathleen Dracup. "Gender-specific characteristics of individuals with depressive symptoms and coronary heart disease." Heart & Lung 40, no. 3 (May 2011): e4-e14. http://dx.doi.org/10.1016/j.hrtlng.2010.04.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Rajib, Dutta. "Role of neuron specific enolase as a biomarker in Parkinson’s disease." Journal of Neuroscience and Neurological Disorders 5, no. 2 (July 6, 2021): 061–68. http://dx.doi.org/10.29328/journal.jnnd.1001052.

Full text

Abstract:

Parkinson’s disease (PD) is thought to be the most common neurodegenerative disease with movement disorder. The key motor symptoms are rigidity, tremor, akinesis/hypokinesia/bradykinesia, and postural instability. However, in our day-to-day clinical practice we tend to see several other symptoms which may be motor or non-motor. Non-motor symptoms (NMS) are quite common and debilitating. The pathological hallmarks of PD are loss of dopaminergic neurons in the substantia nigra pars compacta (SNPc) and accumulation of unfolded or misfolded alpha-synuclein. Diagnosis of PD is difficult in the pre-motor stage. Late diagnosis renders a substantial loss of dopaminergic neurons in SNPc and spread of disease in other parts of the brain. This may manifest as either full blown symptoms requiring multiple medications or may even lead to life threatening condition due to lack of early diagnostic tools and techniques. Biomarkers are required to diagnose PD at a very early stage when prevention is possible. Hence, we see a lot of interest among researchers involved in finding a biomarker specific to the disease. Biomarkers may be clinical, image based, genetic, and biochemical. Cerebrospinal fluid (CSF) and serum markers which may correlate with disease pathophysiology are of great significance. One such molecule which recently gained a lot of attention is neuron-specific enolase (NSE). The main aim of this paper is to highlight the role of NSE in predicting neurodegeneration and neuroinflammation ultimately reflecting damage of brain cells in PD.

APA, Harvard, Vancouver, ISO, and other styles

26

Skalicky, Anne M., Sameer R. Ghate, Jose Ricardo Perez, and Anne M. Rentz. "Results of a Qualitative Study to Develop a Patient Reported Outcome Measure for Patients with 4 Subtypes of Soft Tissue Sarcoma." Sarcoma 2017 (2017): 1–11. http://dx.doi.org/10.1155/2017/6868030.

Full text

Abstract:

Objective. The objective of this research was to develop a disease-specific symptom inventory for soft tissue sarcoma. Methods. Literature review and clinical expert and patient interviews were conducted to determine disease-specific symptoms important to patients with one of the four STS subtypes. Clinical experts identified the most relevant STS symptom items from the item pool developed from literature review. Concept elicitation interviews were conducted with patients to elicit their STS symptom experiences followed by a completion of the draft symptom list via web survey. A cognitive interview was conducted on the comprehension and importance of the symptom items. Results. Eighty-three symptom items were compiled and discussed with three clinical experts who identified 26 symptoms specific to the four STS subtypes. A total sample of 27 STS participants with self-reported leiomyosarcoma (74%), undifferentiated sarcoma (15%), synovial sarcoma (7%), or liposarcoma (4%) diagnosis completed the web survey and 10 were interviewed. The draft 12-item STS-specific symptom inventory includes abdominal pain, pressure in abdomen, early satiety, bloating, gastrointestinal pain, muscle pain, bone pain, heavy menstrual flow, shortness of breath, chest pain, cough, and painful menstruation. Conclusion. A number of symptoms are common across STS subtypes and may form a single STS symptom inventory.

APA, Harvard, Vancouver, ISO, and other styles

27

Nuss, Geoffrey R., Michael A. Granieri, Lee C. Zhao, Dennis J. Thum, and Chris M. Gonzalez. "Presenting Symptoms of Anterior Urethral Stricture Disease: A Disease Specific, Patient Reported Questionnaire to Measure Outcomes." Journal of Urology 187, no. 2 (February 2012): 559–62. http://dx.doi.org/10.1016/j.juro.2011.10.043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Irene, Rasanu. "Genitourinary Dysfunction Prevalence in Parkinson Disease Patients." ARS Medica Tomitana 25, no. 1 (February 1, 2019): 6–10. http://dx.doi.org/10.2478/arsm-2019-0002.

Full text

Abstract:

Abstract The goal of this study was to estimate the prevalence of patient-reported genitourinary dysfunction symptoms in Parkinson’s disease patients from the Southeastern Romania. The study was performed on 86 patients with idiopathic Parkinson’s disease from 5 Outpatients Clinics of Constanta, 56% males, mean age 70.6 years, mean disease duration 6.33 years. The patients have been assessed for the presence of genitourinary symptoms using the Scale for Outcomes in Parkinson’s Disease for Autonomic Symptoms (SCOPA-AUT) as a self-administered questionnaire. The vast majority of study population (98.8%) reported at least one genitourinary dysfunction. The most common urinary symptom was nocturia (95.3%, 95% CI 90.8-99.7), followed by pollakiuria (82.5%, 95% CI 74.4-90.5), difficulty passing urine and urge to urinate (each present in 76.7% of studied PD patients, 95% CI 67.4-85.3), incomplete bladder emptying (75.5%, 95% CI 66.4-84.5), urinary incontinence (67.4%, 95% CI 57.5-77.3). As frequency, most of the study subjects experienced genitourinary symptoms only “sometimes”. None of the investigated PD patients affected by genitourinary symptoms used specific medication therapy.

APA, Harvard, Vancouver, ISO, and other styles

29

Kulyk, A., J. Stone, and C. N. Bernstein. "A258 ASSOCIATION BETWEEN SYMPTOMS AND INFLAMMATORY BOWEL DISEASE ACTIVITY USING INFLAMMATORY BOWEL DISEASE SYMPTOM INVENTORY – A RETROSPECTIVE ANALYSIS FROM THE MANITOBA LIVING WITH IBD STUDY." Journal of the Canadian Association of Gastroenterology 3, Supplement_1 (February 2020): 135–36. http://dx.doi.org/10.1093/jcag/gwz047.257.

Full text

Abstract:

Abstract Background Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gut and includes predominantly Crohn’s disease (CD) and ulcerative colitis (UC). The Inflammatory Bowel Disease Symptom Inventory (IBDSI), developed at the University of Manitoba is a validated patient self-report symptom inventory which has shown to demonstrate good validity to accepted clinician-based assessments of disease activity. The IBDSI focuses of 5 main symptom clusters: bowel symptoms, abdominal discomfort, fatigue, bowel complications, and systemic complications. While there is good evidence for the presence of these symptoms in IBD, there has yet to be an analysis of the correlation between specific symptom clusters and active IBD. Aims Our aim is to identify symptoms experienced by patients with IBD being followed prospectively over one year and further analyze which of these symptoms are correlated with disease activity. Methods 155 patients enrolled in the Manitoba Living with IBD Study were eligible for the current study. Bi-weekly IBDSI short-form survey results were analyzed to determine which IBD-related symptoms were experienced by each patient over the study period (1 year). Descriptive data for symptoms will be reported, and will then be compared to disease activity (defined in Crohn’s disease as an IBDSI score >14 and in UC>13 and fecal calprotectin level (FCAL) >250 ug/g) to determine which symptoms most correlate with active IBD. Results The study population ranged from ages 18–70, with a mean age of 43 years. 30.3% (47) of the population were male. 65.8% (102) of the population consisted of CD, 31.0% (48) had UC, the remaining 3.2% (5) had IBD-type unclassified. Some of the symptoms for analysis will include abdominal pain, frequency and consistency of bowel movements, blood within the stool, and other associated symptoms such as nausea and loss of appetite. The results for the frequency of symptoms reported and which are most correlated with disease activity is still under analysis. Conclusions This will be the first study assessing the association between symptoms experienced by subjects contrasted to disease activity using the self-reported measurement IBDSI and FCAL. Funding Agencies None

APA, Harvard, Vancouver, ISO, and other styles

30

Alahdal, Abdulrahman M. "Misdiagnosed Celiac Disease:." Saudi Journal of Internal Medicine 7, no. 1 (June 30, 2017): 43–46. http://dx.doi.org/10.32790/sjim.2017.7.1.7.

Full text

Abstract:

The advancement of technologies including the availability of sensitive and specific serological screenings and endoscopic intestinal examinations has led to increased awareness and recognition of silent epidemic celiac disease in patients with irritable bowel syndrome in the last two decades. The objective of this case report is to describe the importance of routine screening of celiac disease in patients with non-specific (common) intestinal symptoms, particularly those with irritable bowel syndrome. The author reported the clinical progress of a 44-year-old Saudi male patient presented with non-specific intestinal symptoms initially misdiagnosed with irritable bowel syndrome. The investigations, including serological testing and endoscopic duodenal biopsy, revealed that the patient had celiac disease. After a course of gluten-free diet, his intestinal symptoms significantly improved. This case report emphasizes the importance of thorough investigations for patients with irritable bowel syndrome to exclude celiac disease.

APA, Harvard, Vancouver, ISO, and other styles

31

Mesa, Ruben A., and Francesco Passamonti. "Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden." American Society of Clinical Oncology Educational Book, no. 36 (May 2016): e324-e335. http://dx.doi.org/10.1200/edbk_159322.

Full text

Abstract:

Individualized medicine is important for patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia, polycythemia vera, and myelofibrosis, which are heterogeneous in terms of genetic mutation profile, prognosis, disease burden, and symptoms. Status of MPN driver mutations in JAK2, CALR, and MPL (or lack of one of these mutations) and other myeloid mutations (ASXL1, SRSF2, CBL, and IDH1/2, among others) affects diagnosis and prognosis. Management begins with estimating the prognosis, disease burden including MPN symptoms, and prevention of vascular events. Allogeneic stem cell transplantation is the definitive therapy in a subset of patients with myelofibrosis, the majority of whom receive JAK inhibition with ruxolitinib to relieve splenomegaly and symptoms and to prolong survival. Ruxolitinib is now a second-line therapy in polycythemia vera, with pegylated interferon being evaluated as a potential front-line therapy compared with hydroxyurea. The therapeutic landscape is evolving to include new JAK inhibitors, which may affect cytopenias (pacritinib and momelotinib), combination therapies including ruxolitinib, and novel targets such as pentraxin and telomerase. Assessing the therapeutic efficacy (including symptom impact) and toxicity of these new approaches is necessary to determine longitudinal management of MPNs in clinical practice and is a key component of “individualizing” care for patients with MPNs.

APA, Harvard, Vancouver, ISO, and other styles

32

Fernandez, Hubert H., Reiner H. See, Matthew F. Gary, Dawn Bowers, Ramon L. Rodriguez, Charles Jacobson, and Michael S. Okun. "Depressive Symptoms in Parkinson Disease Correlate With Impaired Global and Specific Cognitive Performance." Journal of Geriatric Psychiatry and Neurology 22, no. 4 (May 8, 2009): 223–27. http://dx.doi.org/10.1177/0891988709335792.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Clemens, J. Quentin. "Is patient reporting of interstitial cystitis symptoms comparable between two disease-specific indices?" Nature Clinical Practice Urology 2, no. 6 (June 2005): 278–79. http://dx.doi.org/10.1038/ncpuro0208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Vallis, T. Michael, and Geoffrey K. Turnbull. "Impact of Disease Activity on the Quality of Life of Crohn’s Disease Patients." Canadian Journal of Gastroenterology 10, no. 5 (1996): 310–15. http://dx.doi.org/10.1155/1996/385479.

Full text

Abstract:

Crohn’s disease (CD) patients often suffer severe symptoms that impair their quality of life. A sample of 39 CD patients who were assessed using well validated measures of disease activity and disease-specific quality of life is reported. Twenty-six of these patients were reassessed an average of four months after the initial assessment to determine the impact of changes in disease activity on quality of life. For the total sample (n=39) disease activity did not predict quality of life for any of the scales of the Inflammatory Bowel Disease Questionnaire (IBDQ) (r<0.13 for each). Thus, examining fluctuations in disease activity between patients did not demonstrate a disease activity-quality of life relationship. In contrast, changes in disease activity within the same individuals over time (the repeat assessment sample, n=26) were correlated with changes in quality of life; increases in disease activity predicted decreases in quality of life on the IBDQ bowel symptoms subscale (r=-0.463, P<0.01) and the IBDQ systemic symptoms subscale (r=0.44, P<0.05). The 10 patients with the largest decrease in disease activity over time (mean decrease of 43.54 points using the Dutch Activity Index) had significant improvement in quality of life on the bowel and systemic subscales. In contrast, the nine patients with the largest increase in disease activity over time (mean increase of 20.57 points using the Dutch Activity Index) had significant reduction in quality of life on the bowel and systemic symptoms subscales. These differences between extreme groups were significant for both the bowel symptoms (P<0.05) and systemic symptoms (P<0.05) subscales. The authors conclude that changes in disease activity affect some important aspects of quality of life: aspects related to disease-specific (bowel symptoms) and nondisease-specific (systemic symptoms) physical symptoms. Importantly, disease activity was not able to predict the emotional and social aspects of IBD-related quality of life. This suggests that nondisease factors need to be considered when working with CD patients. Future research should evaluate the role of psychological intervention in improving quality of life for patients with reduced well-being, particularly in areas of emotional and social functioning.

APA, Harvard, Vancouver, ISO, and other styles

35

Samir, Gendy. "Audit of the effect of non-nasal specific scoring on the Postoperative SNOT22 questionnaire." Advanced Treatments in ENT Disorders 4, no. 1 (September 23, 2020): 003–5. http://dx.doi.org/10.29328/journal.ated.1001010.

Full text

Abstract:

The Sino-nasal outcome test (SNOT22) has been widely adopted in clinical practice and has been declared as the most suitable sinonasal outcome scoring system. It is simple disease specific encompassing 22 symptoms reflecting health burden of the rhino- logical patients. Each item quantifies symptoms severity from 0(no problem) to 5 (worst symptom). The sum of each item results in a maximum score of 110. High score indicates poor outcome.

APA, Harvard, Vancouver, ISO, and other styles

36

Neijenhuis, Myrte K., Tom J. G. Gevers, Marie C. Hogan, Patrick S. Kamath, Titus F. M. Wijnands, Ralf C. P. M. van den Ouweland, Marie E. Edwards, Jeff A. Sloan, Wietske Kievit, and Joost P. H. Drenth. "Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease." Hepatology 64, no. 1 (April 15, 2016): 151–60. http://dx.doi.org/10.1002/hep.28545.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Haapamäki, Johanna, Ulla Turunen, Risto P. Roine, Martti A. Färkkilä, and Perttu E. T. Arkkila. "Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease." Quality of Life Research 18, no. 8 (July 23, 2009): 961–69. http://dx.doi.org/10.1007/s11136-009-9514-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Seabury, Jamison, Christine Zizzi, Jennifer Weinstein, Ellen Wagner, Spencer Rosero, Nuran Dilek, Aaron Kaat, et al. "RESULTS FROM A NATIONAL CROSS-SECTIONAL STUDY OF DISEASE BURDEN IN CROHN’S DISEASE." Inflammatory Bowel Diseases 27, Supplement_1 (January 1, 2021): S13. http://dx.doi.org/10.1093/ibd/izaa347.032.

Full text

Abstract:

Abstract Background Patients with Crohn’s disease experience a wide variety of clinical symptoms that affect how they feel and function. As therapeutic trials are planned for patients with Crohn’s disease, it is important to better understand the symptoms that have the greatest impact on Crohn’s disease patient’s lives. Objective To identify the most common and important disease manifestations in Crohn’s disease in a large population of patients. To determine the modifying factors that are associated with these symptoms. Methods We conducted a national cross-sectional study of 415 patients from the IBD Partners patient registry sponsored by the Crohn’s & Colitis Foundation to identify the prevalence and relative importance of 148 individual symptoms across 17 unique symptomatic themes. These themes were previously identified through 16 semi-structured qualitative interviews with Crohn’s patients. Results Crohn’s disease participants provided over 55,000 symptom rating responses. The symptomatic themes with the highest prevalence in Crohn’s disease were gastrointestinal issues (93.0%), fatigue (86.4%), dietary restrictions (77.9%), impaired sleep or daytime sleepiness (75.6%), and inability to do activities (72.3%). Symptomatic theme prevalence was widely associated with having above the median number of stools per day, having above the median number of bowel movements per day, having perianal disease, having to miss work, and unemployment. Discussion/Conclusion: Crohn’s disease symptoms, some under-recognized, vary based on disease characteristics and demographic features. These symptoms represent targets for future therapeutic interventions and are potential areas of interest for an upcoming disease-specific patient-reported outcome measure for this population. Acknowledgements Funding for this project was provided by UR Ventures. Research activities were conducted in collaboration with the Crohn’s & Colitis Foundation.

APA, Harvard, Vancouver, ISO, and other styles

39

Vuckovic, Karen M., Rebecca (Schuetz) Bierle, and Catherine J. Ryan. "Navigating Symptom Management in Heart Failure: The Crucial Role of the Critical Care Nurse." Critical Care Nurse 40, no. 2 (April 1, 2020): 55–63. http://dx.doi.org/10.4037/ccn2020685.

Full text

Abstract:

High-acuity, progressive care, and critical care nurses often provide care for patients with heart failure during an exacerbation of acute disease or at the end of life. Identifying and managing heart failure symptoms is complex and requires early recognition and early intervention. Because symptoms of heart failure are not disease specific, patients may not respond to them appropriately, resulting in treatment delays. This article reviews the complexities and issues surrounding the patient’s ability to recognize heart failure symptoms and the critical care nurse’s role in facilitating early intervention. It outlines the many barriers to symptom recognition and response, including multimorbidities, age, symptom intensity, symptom escalation, and health literacy. The influence of self-care on heart failure management is also described. The critical care nurse plays a crucial role in teaching heart failure patients to identify and respond appropriately to their symptoms, thus promoting early intervention.

APA, Harvard, Vancouver, ISO, and other styles

40

Stefanova, Elka, Ljubomir Ziropadja, Mirjana Petrović, Tanja Stojković, and Vladimir Kostić. "Screening for Anxiety Symptoms in Parkinson Disease." Journal of Geriatric Psychiatry and Neurology 26, no. 1 (February 13, 2013): 34–40. http://dx.doi.org/10.1177/0891988713476368.

Full text

Abstract:

Background: A limited number of studies examined anxiety in Parkinson disease (PD). Questionable validity of the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) defined anxiety disorders in PD population as well as a lack of validated rating scales hampered the investigation in this field. Objective: To screen for prevalence of anxiety symptoms and their associated demographic and clinical features in an outpatient-based cohort with PD. Patients and methods: A consecutive series of 360 patients with PD underwent investigation with the Hamilton Anxiety Rating Scale (HARS), the 17-item Hamilton Depression Rating Scale, Neuropsychiatric Inventory, section E (anxiety), motor scoring with Hoehn and Yahr staging, the Unified Parkinson’s Disease Rating Scale, and cognitive screening with the Mini-Mental State Examination. Results: In all, 136 (37.8%) patients with PD of our cohort had anxiety symptoms, whereas both depression and anxiety were recorded in 5.6% of the patients, while in 56.7% neither anxiety nor depression was present. Female gender, motor disability, and core depression symptoms were the main markers of anxiety in patients with PD. The severity of anxiety symptoms was not associated with asymmetry of motor symptoms. Education, disease duration, and levodopa dose were poor predictors in the model. The HARS had a satisfactory inter-item correlation, convergent validity, and factorial structure. Conclusions: Anxiety may be present as an isolated symptom, with specific demographic and clinical markers, and not only as a feature of depression in PD population. This highlighted the importance of identifying anxiety symptoms when treating patients with PD.

APA, Harvard, Vancouver, ISO, and other styles

41

Robinson, Stephanie M., Ramona McLoughlin, and Shaun T. O'Keeffe. "Coeliac disease in the older person." Reviews in Clinical Gerontology 23, no. 1 (October 12, 2012): 32–42. http://dx.doi.org/10.1017/s0959259812000159.

Full text

Abstract:

SummaryCoeliac disease (CD) results from immunologically mediated inflammation of the small intestinal mucosa precipitated by ingestion of gluten in wheat and other cereals in genetically susceptible people. There is a broad spectrum of clinical and histological features associated with gluten sensitivity. Overt clinical malabsorption is uncommon, and clinical symptoms are often non-specific. This is particularly true of older people and the diagnosis of CD may be delayed or missed as a result. The incidence of metabolic bone disease, neurological symptoms and nutritional deficiencies are high in older people with CD and respond well to treatment. Sensitive and specific serological tests are now available and these have improved ease of detection of CD in patients without classical symptoms. Hence, a high index of suspicion is warranted in older people with potential symptoms of CD.

APA, Harvard, Vancouver, ISO, and other styles

42

Baumann, Fanni, Steven Hebert, Wolfgang Rascher, Joachim Woelfle, and Chara Gravou-Apostolatou. "Clinical Characteristics of the End-of-Life Phase in Children with Life-Limiting Diseases: Retrospective Study from a Single Center for Pediatric Palliative Care." Children 8, no. 6 (June 19, 2021): 523. http://dx.doi.org/10.3390/children8060523.

Full text

Abstract:

Background: Data on the end-of-life phase of children receiving palliative care are limited. The purpose of this study is to investigate the spectrum of symptoms of terminally ill children, adolescents, and young adults, depending on their underlying disease. Methods: Findings are based on a 4.5-year retrospective study of 89 children who received palliative care before they died, investigating the symptomatology of the last two weeks before death. Results: In this study, the most common clinical symptomatology present in children undergoing end-of-life care includes pain, shortness of breath, anxiety, nausea, and constipation. Out of 89 patients included in this study, 47% suffered from an oncological disease. Oncological patients had a significantly higher symptom burden at the end of life (p < 0.05) compared to other groups, and the intensity of symptoms increased as the underlying disease progressed. The likelihood of experiencing pain and nausea/vomiting was also significantly higher in oncological patients (p = 0.016). Conclusions: We found that the underlying disease is associated with marked differences in the respective leading clinical symptom. Therefore, related to these differences, symptom management has to be adjusted according to the underlying disease, since the underlying disorder seems to exert an influence on the severity of symptoms and thereby on the modality and choice of treatment. This study is intended to aid underlying disease-specific symptom management at the end-of-life care for children, adolescents, and young adults, with a specific focus on end-of-life care in a home environment.

APA, Harvard, Vancouver, ISO, and other styles

43

Suzina, A. H., M. Hamzah, and A. R. Samsudin. "Objective assessment of nasal resistance in patients with nasal disease." Journal of Laryngology & Otology 117, no. 8 (August 2003): 609–13. http://dx.doi.org/10.1258/002221503768199933.

Full text

Abstract:

Nasal obstruction is a subjective complaint in patients with nasal disease.The ability to quantitate the nasal ventilation dysfunction would be useful for making the appropriate choice of nasal disease management. This cross-sectional study comprised of 200 adult subjects. They underwent assessment of relevant symptoms, nasal examination and investigations before undergoing active anterior rhinomanometry (AAR) assessment. A group of 88 normal subjectsand 112 patients with nasal disease were included. The mean total nasal air resistance (NAR) was significantly higher in patients with nasal disease (0.33 Pa/cm3/s) as compared tonormal subjects (0.24 Pa/cm3/s). There was no significant difference in total NAR between patients with symptoms of nasal obstruction and those without the symptoms (p = 0.42). It is concluded that AAR is a sensitive but not a specific tool for the detection of abnormalities in NAR and it failed to relate to the symptom of nasal obstruction.

APA, Harvard, Vancouver, ISO, and other styles

44

Janssens, Thomas, Zora Van de Moortel, Wolfgang Geidl, Johannes Carl, Klaus Pfeifer, Nicola Lehbert, Michael Wittmann, Konrad Schultz, and Andreas von Leupoldt. "Impact of Disease-Specific Fears on Pulmonary Rehabilitation Trajectories in Patients with COPD." Journal of Clinical Medicine 8, no. 9 (September 13, 2019): 1460. http://dx.doi.org/10.3390/jcm8091460.

Full text

Abstract:

Disease-specific fears predict health status in chronic obstructive pulmonary disease (COPD), but their role in pulmonary rehabilitation (PR) remains poorly understood and especially longer-term evaluations are lacking. We therefore investigated changes in disease-specific fears over the course of PR and six months after PR, and investigated associations with PR outcomes (COPD assessment test (CAT) and St. Georges respiratory questionnaire (SGRQ)) in a subset of patients with COPD (n = 146) undergoing a 3-week inpatient PR program as part of the STAR study (Clinicaltrials.gov, ID: NCT02966561). Disease-specific fears as measured with the COPD anxiety questionnaire improved after PR. For fear of dyspnea, fear of physical activity and fear of disease progression, improvements remained significant at six-month follow-up. Patients with higher disease-specific fears at baseline showed elevated symptom burden (CAT and SGRQ Symptom scores), which persisted after PR and at follow-up. Elevated disease-specific fears also resulted in reduced improvements in Quality of Life (SGRQ activity and impact scales) after PR and at follow-up. Finally, improvement in disease-specific fears was associated with improvement in symptom burden and quality of life. Adjustment for potential confounding variables (sex, smoking status, age, lung function, and depressive symptoms) resulted in comparable effects. These findings show the role of disease-specific fears in patients with COPD during PR and highlight the need to target disease-specific fears to further improve the effects of PR.

APA, Harvard, Vancouver, ISO, and other styles

45

Doyle, Todd, Scott Palmer, Julie Johnson, Michael A. Babyak, Patrick Smith, Stephanie Mabe, Karen Welty-Wolf, Tereza Martinu, and James A. Blumenthal. "Association of Anxiety and Depression with Pulmonary-Specific Symptoms in Chronic Obstructive Pulmonary Disease." International Journal of Psychiatry in Medicine 45, no. 2 (February 2013): 189–202. http://dx.doi.org/10.2190/pm.45.2.g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Ray Chaudhuri, K., Pablo Martinez-Martin, Angelo Antonini, Richard G. Brown, Joseph H. Friedman, Marco Onofrj, Erwin Surmann, Liesbet Ghys, and Claudia Trenkwalder. "Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER." Parkinsonism & Related Disorders 19, no. 7 (July 2013): 660–65. http://dx.doi.org/10.1016/j.parkreldis.2013.02.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Kong, Lingfang, Jianxiang Wu, Lina Lu, Yi Xu, and Xueping Zhou. "Interaction between Rice stripe virus Disease-Specific Protein and Host PsbP Enhances Virus Symptoms." Molecular Plant 7, no. 4 (April 2014): 691–708. http://dx.doi.org/10.1093/mp/sst158.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Krantz, Gunilla, and Per-Olof Östergren. "Women's health: do common symptoms in women mirror general distress or specific disease entities?" Scandinavian Journal of Public Health 27, no. 4 (October 1999): 311–17. http://dx.doi.org/10.1177/14034948990270040501.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Rajendran, N., and D. Kumar. "Food-specific IgG4-guided exclusion diets improve symptoms in Crohn’s disease: a pilot study." Colorectal Disease 13, no. 9 (July 7, 2010): 1009–13. http://dx.doi.org/10.1111/j.1463-1318.2010.02373.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Hii, G., R. Pennington, S. Hartson, C. D. Taylor, R. Lartey, A. Williams, D. Lewis, and U. Melcher. "Isolate-specific synergy in disease symptoms between cauliflower mosaic and turnip vein-clearing viruses." Archives of Virology 147, no. 7 (July 2002): 1371–84. http://dx.doi.org/10.1007/s00705-002-0812-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Disease-Specific Symptoms'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles